The Experts below are selected from a list of 69 Experts worldwide ranked by ideXlab platform
Markku Jarvinen - One of the best experts on this subject based on the ideXlab platform.
-
An outcome study of chronic patellofemoral pain syndrome : Seven-year follow-up of patients in a randomized, controlled trial
Journal of Bone and Joint Surgery American Volume, 1999Co-Authors: Pekka Kannus, A Natri, Timo Paakkala, Markku JarvinenAbstract:Background: We determined prospectively the long-term outcomes of nonoperative treatment of chronic patellofemoral pain syndrome. Methods: Of forty-nine patients in a prospective, randomized, double-blind study of unilateral chronic patellofemoral pain syndrome in the knee, forty-five were reexamined seven years after the initial trial of treatment. In the earlier trial, the short-term (six-month) effects of intra-articular injections of Glycosaminoglycan Polysulfate combined with intensive quadriceps-muscle exercises were compared with those of injections of a placebo combined with exercises and with those of exercises alone. At seven years, the follow-up consisted of standardized subjective, functional, and clinical assessments and muscle-strength measurements as well as magnetic resonance imaging, radiography, and bone-densitometry measurements of the knee. Results: At six months, complete subjective, functional, and clinical recovery had occurred in almost three-fourths of the patients and, with the numbers available for study, neither significant nor clinically important differences among the three initial treatment groups were detected. The subjective and functional parameters showed few changes between six months and seven years; almost three-fourths of the patients still had full subjective and functional recovery at the time of the latest follow-up. However, according to the physician's clinical evaluation, the number of patients who had no symptoms on the patellar compression and apprehension tests decreased over time, from forty-two (93 percent) and forty (89 percent) of forty-five patients at six months to thirty (67 percent) and thirty-one (69 percent) at seven years; these changes were significant (p = 0.002 and p = 0.023, respectively). The number of patients who had crepitation on the patellar compression test increased over time, from twenty-six (58 percent) at six months to thirty-six (80 percent) at seven years (p = 0.021). The physician's overall assessment showed a similar trend, with thirty-four patients (76 percent) having had complete recovery at six months compared with thirty (67 percent) at seven years; however, with the numbers available, this change was not significant (p = 0.420). Magnetic resonance imaging, performed for thirty-seven patients, revealed no abnormalities in twenty-four (65 percent), mild abnormalities in four (11 percent), moderate abnormalities (a 25 to 75 percent decrease in the thickness of the cartilage) in seven (19 percent), and overt patellofemoral osteoarthritis in two (5 percent) at seven years. Conclusions: The seven-year overall outcome was good in approximately two-thirds of the patients. However, the remaining patients still had symptoms or objective signs of a patellofemoral abnormality.
-
effect of intraarticular Glycosaminoglycan Polysulfate treatment on patellofemoral pain syndrome a prospective randomized double blind trial comparing Glycosaminoglycan Polysulfate with placebo and quadriceps muscle exercises
Arthritis & Rheumatism, 1992Co-Authors: Pekka Kannus, A Natri, S Niittymaki, Markku JarvinenAbstract:Objective. To compare the effects of intraarticular (IA) injections of Glycosaminoglycan Polysulfate (GAGPS) plus basic conservative treatment with the effects of placebo injections plus conservative treatment and with the effects of conservative treatment alone in patients with chronic patellofemoral pain syndrome (PFPS). Methods. We treated 53 patients who presented with chronic PFPS in 1 knee, according to 1 of the 3 protocols, in a prospective, randomized, double-blind study. Basic conservative treatment consisted of a 6-week program of quadriceps muscle exercise, elimination of symptom-producing activities, and oral doses of nonsteroidal antiinflammatory drugs. Physiologic saline served as placebo for injection. During the 6-week treatment period, 5 injections were given 1 week apart. Along with measurements of quadriceps strength, standardized subjective, functional, and clinical assessments were performed at presentation, after 6 weeks of treatment, and after 6 months. Results. Results at 6 months indicated that IA injections of GAGPS or saline did not result in significant improvement beyond the good results achieved by the basic conservative treatment alone. More than two-thirds of the patients in each group experienced complete recovery. Conclusion. Neither the GAGPS injections nor the physiologic saline injections are more effective than conservative therapy in the treatment of chronic PFPS. Restoration of normal quadriceps muscle function to the affected knee seems to be crucial in treating PFPS.
-
Effect of intraarticular Glycosaminoglycan Polysulfate treatment on patellofemoral pain syndrome. A prospective, randomized double‐blind trial comparing Glycosaminoglycan Polysulfate with placebo and quadriceps muscle exercises
Arthritis & Rheumatism, 1992Co-Authors: Pekka Kannus, A Natri, S Niittymaki, Markku JarvinenAbstract:Objective. To compare the effects of intraarticular (IA) injections of Glycosaminoglycan Polysulfate (GAGPS) plus basic conservative treatment with the effects of placebo injections plus conservative treatment and with the effects of conservative treatment alone in patients with chronic patellofemoral pain syndrome (PFPS). Methods. We treated 53 patients who presented with chronic PFPS in 1 knee, according to 1 of the 3 protocols, in a prospective, randomized, double-blind study. Basic conservative treatment consisted of a 6-week program of quadriceps muscle exercise, elimination of symptom-producing activities, and oral doses of nonsteroidal antiinflammatory drugs. Physiologic saline served as placebo for injection. During the 6-week treatment period, 5 injections were given 1 week apart. Along with measurements of quadriceps strength, standardized subjective, functional, and clinical assessments were performed at presentation, after 6 weeks of treatment, and after 6 months. Results. Results at 6 months indicated that IA injections of GAGPS or saline did not result in significant improvement beyond the good results achieved by the basic conservative treatment alone. More than two-thirds of the patients in each group experienced complete recovery. Conclusion. Neither the GAGPS injections nor the physiologic saline injections are more effective than conservative therapy in the treatment of chronic PFPS. Restoration of normal quadriceps muscle function to the affected knee seems to be crucial in treating PFPS.
Leslie C Morey - One of the best experts on this subject based on the ideXlab platform.
-
treatment of primary degenerative dementia and multi infarct dementia with Glycosaminoglycan Polysulfate a comparison of two diagnoses and two doses
Current Therapeutic Research-clinical and Experimental, 1993Co-Authors: L Conti, Leslie C Morey, O K Fjetland, Dario Grossi, G B Cassano, G F Placidi, A Modafferi, A Postiglione, F Lazzerini, F ReAbstract:Abstract Glycosaminoglycan Polysulfate is a mixture of sulfomucopolysaccharides with a standardized composition and reproducible biologic activity. In a 12-week, multicenter clinical trial the therapeutic effects of two dosages—250 lipasemic-releasing units (LRU) per day and 500 LRU/day—of parenterally administered Glycosaminoglycan Polysulfate were compared in two diagnostically distinct populations: (1) patients with primary degenerative dementia of the Alzheimer type, and (2) patients with multi-infarct dementia. It was found that there were significant changes from pretreatment to end of therapy with regard to measures of objective performance, psychopathology, and social behavior. Improvement was consistently greater in the group with primary degenerative dementia than in the group with multi-infarct dementia. On the other hand, no consistent differences in therapeutic effects between the two doses could be seen. The drug was well tolerated; side effects were infrequent and mild. No clinically significant laboratory abnormalities were encountered during the 3-month clinical trial.
-
early manifestations of dementing illness treatment with Glycosaminoglycan Polysulfate
Progress in Neuro-psychopharmacology & Biological Psychiatry, 1992Co-Authors: Leslie C Morey, O K Fjetland, Franco Rengo, Nicola Ferrara, Virgilio Agnetti, Marina Donofrio, Giulio Facchini, Fernando Anzivino, Maria Alessandra Perego, Chiara DaneseAbstract:Abstract 1. In a multicenter, placebo-controlled, double-blind clinical trial in 156 elderly patients with psychopathologic symptoms, Glycosaminoglycan Polysulfate was found to be a therapeutlcally effective agent in the treatment of the earliest manifestations of a dementing process. 2. Treatment with Glycosaminoglycan Polysulfate in the daily dosage of 600 LRU, administered on the basis of a divided dosage schedule for 24 weeks, was significantly superior to an inactive placebo on several several outcome measures including the SCAG Total and factor scores (i.e., Cognitive Dysfunction, Withdrawal, Agitation/Irritability and Depression), the NOHLIS Total and Fatiguability factor scores, the MMSE, the HAM-D Total and Vegetative Symptoms factor score and the CGI Severity of Illness and Global Improvement. 3. The drug was well tolerated; vital signs and laboratory measures did not show clinically significant changes within the experimental period.
-
Glycosaminoglycan Polysulfate in the treatment of old age dementias
Progress in Neuro-psychopharmacology & Biological Psychiatry, 1991Co-Authors: Leslie C Morey, Eugenio Aguglia, Rafael Madureira Batista, Giuseppe Campanella, L Conti, Jeanfrancois Dreyfus, O K Fjetland, Dario Grossi, Antonino Modaferri, Gustavo A MarinperezAbstract:Abstract Ban, Thomas A. et al: Glycosaminoglycan Polysulfate in the Treatment of Old Age Dementias. Prog. Neuro-Psychopharmacol. & Biol. Psychiat. 1991, 15 :323–342. 1. 1. In a multicenter, placebo-controlled, double-blind clinical trial in 155 elderly patients with cognitive decline, Glycosaminoglycan Polysulfate was found to be a therapeutically effective agent in the treatment of old age dementias. 2. 2. Treatment with Glycosaminoglycan Polysulfate in the daily dosage of 600 LRU, administered on the basis of a divided dosage schedule for 12 weeks, was significantly superior to an inactive placebo on several outcome measures including the Wechsler Memory Scale-Russell Revision (Easy Paired Associates Learning and Immediate Visual Reproduction), Mini Mental State Examination, the Sandoz Clinical Assessment Geriatric (Cognitive Dysfunction and Depression), Hachinski Dementia Scale, Brief Psychiatric Rating Scale (Confusion and Depressive Withdrawal) and Global Improvement Scale of the Clinical Global Impression. 3. 3. Adverse effects with Glycosaminoglycan Polysulfate were few and mild. The drug was equally well tolerated and equally effective in the two major dementias of old age, i.e., primary degenerative and multi-infarct. The number of abnormal laboratory test readings remained essentially unchanged from pre-treatment to post-treatment.
O K Fjetland - One of the best experts on this subject based on the ideXlab platform.
-
treatment of primary degenerative dementia and multi infarct dementia with Glycosaminoglycan Polysulfate a comparison of two diagnoses and two doses
Current Therapeutic Research-clinical and Experimental, 1993Co-Authors: L Conti, Leslie C Morey, O K Fjetland, Dario Grossi, G B Cassano, G F Placidi, A Modafferi, A Postiglione, F Lazzerini, F ReAbstract:Abstract Glycosaminoglycan Polysulfate is a mixture of sulfomucopolysaccharides with a standardized composition and reproducible biologic activity. In a 12-week, multicenter clinical trial the therapeutic effects of two dosages—250 lipasemic-releasing units (LRU) per day and 500 LRU/day—of parenterally administered Glycosaminoglycan Polysulfate were compared in two diagnostically distinct populations: (1) patients with primary degenerative dementia of the Alzheimer type, and (2) patients with multi-infarct dementia. It was found that there were significant changes from pretreatment to end of therapy with regard to measures of objective performance, psychopathology, and social behavior. Improvement was consistently greater in the group with primary degenerative dementia than in the group with multi-infarct dementia. On the other hand, no consistent differences in therapeutic effects between the two doses could be seen. The drug was well tolerated; side effects were infrequent and mild. No clinically significant laboratory abnormalities were encountered during the 3-month clinical trial.
-
early manifestations of dementing illness treatment with Glycosaminoglycan Polysulfate
Progress in Neuro-psychopharmacology & Biological Psychiatry, 1992Co-Authors: Leslie C Morey, O K Fjetland, Franco Rengo, Nicola Ferrara, Virgilio Agnetti, Marina Donofrio, Giulio Facchini, Fernando Anzivino, Maria Alessandra Perego, Chiara DaneseAbstract:Abstract 1. In a multicenter, placebo-controlled, double-blind clinical trial in 156 elderly patients with psychopathologic symptoms, Glycosaminoglycan Polysulfate was found to be a therapeutlcally effective agent in the treatment of the earliest manifestations of a dementing process. 2. Treatment with Glycosaminoglycan Polysulfate in the daily dosage of 600 LRU, administered on the basis of a divided dosage schedule for 24 weeks, was significantly superior to an inactive placebo on several several outcome measures including the SCAG Total and factor scores (i.e., Cognitive Dysfunction, Withdrawal, Agitation/Irritability and Depression), the NOHLIS Total and Fatiguability factor scores, the MMSE, the HAM-D Total and Vegetative Symptoms factor score and the CGI Severity of Illness and Global Improvement. 3. The drug was well tolerated; vital signs and laboratory measures did not show clinically significant changes within the experimental period.
-
Glycosaminoglycan Polysulfate in the treatment of old age dementias
Progress in Neuro-psychopharmacology & Biological Psychiatry, 1991Co-Authors: Leslie C Morey, Eugenio Aguglia, Rafael Madureira Batista, Giuseppe Campanella, L Conti, Jeanfrancois Dreyfus, O K Fjetland, Dario Grossi, Antonino Modaferri, Gustavo A MarinperezAbstract:Abstract Ban, Thomas A. et al: Glycosaminoglycan Polysulfate in the Treatment of Old Age Dementias. Prog. Neuro-Psychopharmacol. & Biol. Psychiat. 1991, 15 :323–342. 1. 1. In a multicenter, placebo-controlled, double-blind clinical trial in 155 elderly patients with cognitive decline, Glycosaminoglycan Polysulfate was found to be a therapeutically effective agent in the treatment of old age dementias. 2. 2. Treatment with Glycosaminoglycan Polysulfate in the daily dosage of 600 LRU, administered on the basis of a divided dosage schedule for 12 weeks, was significantly superior to an inactive placebo on several outcome measures including the Wechsler Memory Scale-Russell Revision (Easy Paired Associates Learning and Immediate Visual Reproduction), Mini Mental State Examination, the Sandoz Clinical Assessment Geriatric (Cognitive Dysfunction and Depression), Hachinski Dementia Scale, Brief Psychiatric Rating Scale (Confusion and Depressive Withdrawal) and Global Improvement Scale of the Clinical Global Impression. 3. 3. Adverse effects with Glycosaminoglycan Polysulfate were few and mild. The drug was equally well tolerated and equally effective in the two major dementias of old age, i.e., primary degenerative and multi-infarct. The number of abnormal laboratory test readings remained essentially unchanged from pre-treatment to post-treatment.
Pekka Kannus - One of the best experts on this subject based on the ideXlab platform.
-
An outcome study of chronic patellofemoral pain syndrome : Seven-year follow-up of patients in a randomized, controlled trial
Journal of Bone and Joint Surgery American Volume, 1999Co-Authors: Pekka Kannus, A Natri, Timo Paakkala, Markku JarvinenAbstract:Background: We determined prospectively the long-term outcomes of nonoperative treatment of chronic patellofemoral pain syndrome. Methods: Of forty-nine patients in a prospective, randomized, double-blind study of unilateral chronic patellofemoral pain syndrome in the knee, forty-five were reexamined seven years after the initial trial of treatment. In the earlier trial, the short-term (six-month) effects of intra-articular injections of Glycosaminoglycan Polysulfate combined with intensive quadriceps-muscle exercises were compared with those of injections of a placebo combined with exercises and with those of exercises alone. At seven years, the follow-up consisted of standardized subjective, functional, and clinical assessments and muscle-strength measurements as well as magnetic resonance imaging, radiography, and bone-densitometry measurements of the knee. Results: At six months, complete subjective, functional, and clinical recovery had occurred in almost three-fourths of the patients and, with the numbers available for study, neither significant nor clinically important differences among the three initial treatment groups were detected. The subjective and functional parameters showed few changes between six months and seven years; almost three-fourths of the patients still had full subjective and functional recovery at the time of the latest follow-up. However, according to the physician's clinical evaluation, the number of patients who had no symptoms on the patellar compression and apprehension tests decreased over time, from forty-two (93 percent) and forty (89 percent) of forty-five patients at six months to thirty (67 percent) and thirty-one (69 percent) at seven years; these changes were significant (p = 0.002 and p = 0.023, respectively). The number of patients who had crepitation on the patellar compression test increased over time, from twenty-six (58 percent) at six months to thirty-six (80 percent) at seven years (p = 0.021). The physician's overall assessment showed a similar trend, with thirty-four patients (76 percent) having had complete recovery at six months compared with thirty (67 percent) at seven years; however, with the numbers available, this change was not significant (p = 0.420). Magnetic resonance imaging, performed for thirty-seven patients, revealed no abnormalities in twenty-four (65 percent), mild abnormalities in four (11 percent), moderate abnormalities (a 25 to 75 percent decrease in the thickness of the cartilage) in seven (19 percent), and overt patellofemoral osteoarthritis in two (5 percent) at seven years. Conclusions: The seven-year overall outcome was good in approximately two-thirds of the patients. However, the remaining patients still had symptoms or objective signs of a patellofemoral abnormality.
-
effect of intraarticular Glycosaminoglycan Polysulfate treatment on patellofemoral pain syndrome a prospective randomized double blind trial comparing Glycosaminoglycan Polysulfate with placebo and quadriceps muscle exercises
Arthritis & Rheumatism, 1992Co-Authors: Pekka Kannus, A Natri, S Niittymaki, Markku JarvinenAbstract:Objective. To compare the effects of intraarticular (IA) injections of Glycosaminoglycan Polysulfate (GAGPS) plus basic conservative treatment with the effects of placebo injections plus conservative treatment and with the effects of conservative treatment alone in patients with chronic patellofemoral pain syndrome (PFPS). Methods. We treated 53 patients who presented with chronic PFPS in 1 knee, according to 1 of the 3 protocols, in a prospective, randomized, double-blind study. Basic conservative treatment consisted of a 6-week program of quadriceps muscle exercise, elimination of symptom-producing activities, and oral doses of nonsteroidal antiinflammatory drugs. Physiologic saline served as placebo for injection. During the 6-week treatment period, 5 injections were given 1 week apart. Along with measurements of quadriceps strength, standardized subjective, functional, and clinical assessments were performed at presentation, after 6 weeks of treatment, and after 6 months. Results. Results at 6 months indicated that IA injections of GAGPS or saline did not result in significant improvement beyond the good results achieved by the basic conservative treatment alone. More than two-thirds of the patients in each group experienced complete recovery. Conclusion. Neither the GAGPS injections nor the physiologic saline injections are more effective than conservative therapy in the treatment of chronic PFPS. Restoration of normal quadriceps muscle function to the affected knee seems to be crucial in treating PFPS.
-
Effect of intraarticular Glycosaminoglycan Polysulfate treatment on patellofemoral pain syndrome. A prospective, randomized double‐blind trial comparing Glycosaminoglycan Polysulfate with placebo and quadriceps muscle exercises
Arthritis & Rheumatism, 1992Co-Authors: Pekka Kannus, A Natri, S Niittymaki, Markku JarvinenAbstract:Objective. To compare the effects of intraarticular (IA) injections of Glycosaminoglycan Polysulfate (GAGPS) plus basic conservative treatment with the effects of placebo injections plus conservative treatment and with the effects of conservative treatment alone in patients with chronic patellofemoral pain syndrome (PFPS). Methods. We treated 53 patients who presented with chronic PFPS in 1 knee, according to 1 of the 3 protocols, in a prospective, randomized, double-blind study. Basic conservative treatment consisted of a 6-week program of quadriceps muscle exercise, elimination of symptom-producing activities, and oral doses of nonsteroidal antiinflammatory drugs. Physiologic saline served as placebo for injection. During the 6-week treatment period, 5 injections were given 1 week apart. Along with measurements of quadriceps strength, standardized subjective, functional, and clinical assessments were performed at presentation, after 6 weeks of treatment, and after 6 months. Results. Results at 6 months indicated that IA injections of GAGPS or saline did not result in significant improvement beyond the good results achieved by the basic conservative treatment alone. More than two-thirds of the patients in each group experienced complete recovery. Conclusion. Neither the GAGPS injections nor the physiologic saline injections are more effective than conservative therapy in the treatment of chronic PFPS. Restoration of normal quadriceps muscle function to the affected knee seems to be crucial in treating PFPS.
L Conti - One of the best experts on this subject based on the ideXlab platform.
-
treatment of primary degenerative dementia and multi infarct dementia with Glycosaminoglycan Polysulfate a comparison of two diagnoses and two doses
Current Therapeutic Research-clinical and Experimental, 1993Co-Authors: L Conti, Leslie C Morey, O K Fjetland, Dario Grossi, G B Cassano, G F Placidi, A Modafferi, A Postiglione, F Lazzerini, F ReAbstract:Abstract Glycosaminoglycan Polysulfate is a mixture of sulfomucopolysaccharides with a standardized composition and reproducible biologic activity. In a 12-week, multicenter clinical trial the therapeutic effects of two dosages—250 lipasemic-releasing units (LRU) per day and 500 LRU/day—of parenterally administered Glycosaminoglycan Polysulfate were compared in two diagnostically distinct populations: (1) patients with primary degenerative dementia of the Alzheimer type, and (2) patients with multi-infarct dementia. It was found that there were significant changes from pretreatment to end of therapy with regard to measures of objective performance, psychopathology, and social behavior. Improvement was consistently greater in the group with primary degenerative dementia than in the group with multi-infarct dementia. On the other hand, no consistent differences in therapeutic effects between the two doses could be seen. The drug was well tolerated; side effects were infrequent and mild. No clinically significant laboratory abnormalities were encountered during the 3-month clinical trial.
-
Glycosaminoglycan Polysulfate in the treatment of old age dementias
Progress in Neuro-psychopharmacology & Biological Psychiatry, 1991Co-Authors: Leslie C Morey, Eugenio Aguglia, Rafael Madureira Batista, Giuseppe Campanella, L Conti, Jeanfrancois Dreyfus, O K Fjetland, Dario Grossi, Antonino Modaferri, Gustavo A MarinperezAbstract:Abstract Ban, Thomas A. et al: Glycosaminoglycan Polysulfate in the Treatment of Old Age Dementias. Prog. Neuro-Psychopharmacol. & Biol. Psychiat. 1991, 15 :323–342. 1. 1. In a multicenter, placebo-controlled, double-blind clinical trial in 155 elderly patients with cognitive decline, Glycosaminoglycan Polysulfate was found to be a therapeutically effective agent in the treatment of old age dementias. 2. 2. Treatment with Glycosaminoglycan Polysulfate in the daily dosage of 600 LRU, administered on the basis of a divided dosage schedule for 12 weeks, was significantly superior to an inactive placebo on several outcome measures including the Wechsler Memory Scale-Russell Revision (Easy Paired Associates Learning and Immediate Visual Reproduction), Mini Mental State Examination, the Sandoz Clinical Assessment Geriatric (Cognitive Dysfunction and Depression), Hachinski Dementia Scale, Brief Psychiatric Rating Scale (Confusion and Depressive Withdrawal) and Global Improvement Scale of the Clinical Global Impression. 3. 3. Adverse effects with Glycosaminoglycan Polysulfate were few and mild. The drug was equally well tolerated and equally effective in the two major dementias of old age, i.e., primary degenerative and multi-infarct. The number of abnormal laboratory test readings remained essentially unchanged from pre-treatment to post-treatment.